• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

新型冠状病毒肺炎防治：氯喹和羟氯喹临床药理学的批判性分析。

COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology.

机构信息

Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

出版信息

PLoS Med. 2020 Sep 3;17(9):e1003252. doi: 10.1371/journal.pmed.1003252. eCollection 2020 Sep.

DOI:10.1371/journal.pmed.1003252
PMID:32881895
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7470382/
Abstract

Nicholas White and coauthors discuss chloroquine and hydroxychloroquine pharmacology in the context of possible treatment of SARS-CoV-2 infection.

摘要

尼古拉斯·怀特（Nicholas White）等人讨论了氯喹和羟氯喹的药理学，以探讨其在治疗 SARS-CoV-2 感染方面的可能作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7370/7470382/e587da9e3e63/pmed.1003252.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7370/7470382/b616faa31a9c/pmed.1003252.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7370/7470382/dbbb022b40d2/pmed.1003252.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7370/7470382/39aaa2403e90/pmed.1003252.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7370/7470382/ab7c94e78833/pmed.1003252.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7370/7470382/e587da9e3e63/pmed.1003252.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7370/7470382/b616faa31a9c/pmed.1003252.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7370/7470382/dbbb022b40d2/pmed.1003252.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7370/7470382/39aaa2403e90/pmed.1003252.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7370/7470382/ab7c94e78833/pmed.1003252.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7370/7470382/e587da9e3e63/pmed.1003252.g005.jpg

相似文献

1
COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology.新型冠状病毒肺炎防治：氯喹和羟氯喹临床药理学的批判性分析。
PLoS Med. 2020 Sep 3;17(9):e1003252. doi: 10.1371/journal.pmed.1003252. eCollection 2020 Sep.
2
Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.氯喹和羟氯喹用于治疗新型冠状病毒肺炎的安全性考量
Clin Microbiol Infect. 2020 Sep;26(9):1276-1277. doi: 10.1016/j.cmi.2020.05.006. Epub 2020 May 16.
3
Insights from nanomedicine into chloroquine efficacy against COVID-19.纳米医学对氯喹治疗 COVID-19 疗效的启示。
Nat Nanotechnol. 2020 Apr;15(4):247-249. doi: 10.1038/s41565-020-0674-9.
4
Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal.氯喹和羟氯喹在 2019 年冠状病毒病（COVID-19）中的应用。事实、虚构和炒作：批判性评价。
Int J Antimicrob Agents. 2020 Sep;56(3):106101. doi: 10.1016/j.ijantimicag.2020.106101. Epub 2020 Jul 17.
5
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
6
Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19).关于氯喹/羟氯喹治疗 2019 年冠状病毒病（COVID-19）的最新情况。
Biosci Trends. 2020 May 21;14(2):156-158. doi: 10.5582/bst.2020.03072. Epub 2020 Apr 13.
7
Do we have enough evidence to use chloroquine/hydroxychloroquine as a public health panacea for COVID-19?我们是否有足够的证据将氯喹/羟氯喹用作应对新冠病毒病的公共卫生万能药？
Clinics (Sao Paulo). 2020;75:e1928. doi: 10.6061/clinics/2020/e1928. Epub 2020 May 8.
8
Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention.羟氯喹在新冠病毒疾病中反应的药代动力学基础：对治疗和预防的启示
Eur J Drug Metab Pharmacokinet. 2020 Dec;45(6):715-723. doi: 10.1007/s13318-020-00640-6.
9
ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.羟氯喹用于 COVID-19 传染病的化学预防（PROLIFIC）以预防一线医护人员感染 COVID-19：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jul 2;21(1):604. doi: 10.1186/s13063-020-04543-4.
10
Chloroquine as a prophylactic agent against COVID-19?氯喹作为 COVID-19 的预防药物？
Int J Antimicrob Agents. 2020 Jun;55(6):105980. doi: 10.1016/j.ijantimicag.2020.105980. Epub 2020 Apr 12.

引用本文的文献

1
Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials.尼帕病毒病的治疗方法：一项支持临床试验候选药物优先级排序的系统评价
Lancet Microbe. 2025 May;6(5):101002. doi: 10.1016/j.lanmic.2024.101002. Epub 2024 Nov 13.
2
Designing a molecularly imprinted polymer-based electrochemical sensor for the sensitive and selective detection of the antimalarial chloroquine phosphate.设计一种基于分子印迹聚合物的电化学传感器，用于灵敏和选择性地检测抗疟药磷酸氯喹。
Mikrochim Acta. 2024 Nov 13;191(12):741. doi: 10.1007/s00604-024-06820-4.
3
Antimalarial Drugs at the Intersection of SARS-CoV-2 and Rheumatic Diseases: What Are the Potential Opportunities?

本文引用的文献

1
Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.羟氯喹和阿奇霉素联合对抗 SARS-CoV-2 的协同抗病毒作用：病毒-宿主相互作用的分子动力学研究揭示了什么。
Int J Antimicrob Agents. 2020 Aug;56(2):106020. doi: 10.1016/j.ijantimicag.2020.106020. Epub 2020 May 13.
2
Concentration-dependent mortality of chloroquine in overdose.氯喹过量致浓度依赖性死亡率。
Elife. 2020 Jul 8;9:e58631. doi: 10.7554/eLife.58631.
3
Hydroxychloroquine for the Prevention of Covid-19 - Searching for Evidence.
抗疟药物在 SARS-CoV-2 和风湿性疾病中的交叉点：有哪些潜在的机会？
Medicina (Kaunas). 2024 Jul 19;60(7):1171. doi: 10.3390/medicina60071171.
4
Mechanisms Underlying the Effects of Chloroquine on Red Blood Cells Metabolism.氯喹对红细胞代谢影响的作用机制。
Int J Mol Sci. 2024 Jun 11;25(12):6424. doi: 10.3390/ijms25126424.
5
Clinical Characteristics, Diagnosis, and Therapeutics of COVID-19: A Review.新型冠状病毒肺炎的临床特征、诊断和治疗：综述。
Curr Med Sci. 2023 Dec;43(6):1066-1074. doi: 10.1007/s11596-023-2797-3. Epub 2023 Oct 14.
6
Antimicrobial and anti-viral effects of selenium nanoparticles and selenoprotein based strategies: COVID-19 and beyond.基于硒纳米颗粒和硒蛋白的策略的抗菌和抗病毒作用：新冠疫情及未来。
J Drug Deliv Sci Technol. 2023 Sep;86:104663. doi: 10.1016/j.jddst.2023.104663. Epub 2023 Jun 8.
7
Hypertension related toxicity of chloroquine explains its failure against COVID-19: Based on rat model.氯喹与高血压相关的毒性解释了其抗COVID-19失败的原因：基于大鼠模型。
Front Pharmacol. 2022 Nov 30;13:1051694. doi: 10.3389/fphar.2022.1051694. eCollection 2022.
8
Hydroxychloroquine induces endothelium-dependent and endothelium-independent relaxation of rat aorta.羟氯喹诱导大鼠主动脉内皮依赖性和非内皮依赖性舒张。
Turk J Med Sci. 2022 Jun;52(3):848-857. doi: 10.55730/1300-0144.5382. Epub 2022 Jun 16.
9
Misinformation about medication during the COVID- 19 pandemic: A perspective of medical staff.关于 COVID-19 大流行期间药物的错误信息：医护人员的视角。
PLoS One. 2022 Oct 27;17(10):e0276693. doi: 10.1371/journal.pone.0276693. eCollection 2022.
10
Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers.健康志愿者吸入式羟氯喹干粉的耐受性和药代动力学评价。
PLoS One. 2022 Aug 5;17(8):e0272034. doi: 10.1371/journal.pone.0272034. eCollection 2022.
羟氯喹预防新型冠状病毒肺炎——寻找证据
N Engl J Med. 2020 Aug 6;383(6):585-586. doi: 10.1056/NEJMe2020388. Epub 2020 Jun 3.
4
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.羟氯喹作为 COVID-19 暴露后预防的随机试验。
N Engl J Med. 2020 Aug 6;383(6):517-525. doi: 10.1056/NEJMoa2016638. Epub 2020 Jun 3.
5
RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.撤回：羟氯喹或氯喹联合或不联合大环内酯类药物治疗新型冠状病毒肺炎：一项多国注册分析
Lancet. 2020 May 22. doi: 10.1016/S0140-6736(20)31180-6.
6
QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin.COVID-19 患者接受羟氯喹/阿奇霉素治疗后出现 QT 间期延长和尖端扭转型室性心动过速。
Heart Rhythm. 2020 Sep;17(9):1425-1433. doi: 10.1016/j.hrthm.2020.05.014. Epub 2020 May 12.
7
Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019.1例2019冠状病毒病患者出现氯喹诱导的尖端扭转型室速
Heart Rhythm. 2020 Sep;17(9):1452-1455. doi: 10.1016/j.hrthm.2020.04.046. Epub 2020 May 5.
8
Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).急件：针对新型冠状病毒病（COVID-19）可能的药物治疗的 QTc 延长和致扭转型心动过速的潜在风险的应对和规避指导建议。
Mayo Clin Proc. 2020 Jun;95(6):1213-1221. doi: 10.1016/j.mayocp.2020.03.024. Epub 2020 Apr 7.
9
Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.氯喹、羟氯喹和阿奇霉素对 SARS-CoV-2 感染患者校正 QT 间期的影响。
Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008662. doi: 10.1161/CIRCEP.120.008662. Epub 2020 Apr 29.
10
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.高剂量与低剂量磷酸氯喹作为辅助治疗对住院的严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染患者的影响：一项随机临床试验。
JAMA Netw Open. 2020 Apr 24;3(4):e208857. doi: 10.1001/jamanetworkopen.2020.8857.